Private company
Oncorus, Inc.
American pharmaceutical preparations company, incorporated in Delaware1
In its 2023 annual report the company says: “We are a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients.”52 It is headquartered in Andover, Massachusetts.1
Last updated Oct 21, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Research and development | $24.0M3 | $27.2M4 | $44.7M5 | $54.7M5 | ||
| Operating expenses | $64.8M5 | $76.5M5 | ||||
| Operating income | -$31.2M3 | -$37.2M4 | -$64.8M5 | -$76.5M5 | ||
| Income tax | $03 | $04 | $05 | $05 | ||
| Net income | -$30.7M3 | -$48.3M4 | -$64.8M5 | -$77.4M5 | ||
| Earnings per share | -$2.565 | -$2.995 | ||||
| Earnings per share (diluted) | -$2.565 | -$2.995 | ||||
| Shares (weighted, basic) | 25.3K shares5 | 25.9K shares5 | ||||
| Shares (weighted, diluted) | 25.3K shares5 | 25.9K shares5 |
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Cash | $20.1M3 | $45.3M3 | $130.3M4 | $100.8M5 | $25.7M5 | |
| Current assets | $45.9M3 | $133.4M4 | $129.1M5 | $64.6M5 | ||
| Property, plant and equipment | $23.2M5 | $44.4M5 | ||||
| Total assets | $50.8M3 | $182.3M4 | $201.6M5 | $145.6M5 | ||
| Accounts payable | $13.0M5 | $5.7M5 | ||||
| Short-term debt | $05 | $19.4M5 | ||||
| Current liabilities | $4.9M3 | $6.0M4 | $21.0M5 | $37.2M5 | ||
| Long-term debt | $05 | $20.0M5 | ||||
| Total liabilities | $8.5M3 | $47.6M4 | $71.6M5 | $85.1M5 | ||
| Retained earnings | -$194.6M5 | -$272.0M5 | ||||
| Shareholders’ equity | -$40.1M3 | -$74.3M4 | $134.7M5 | $130.0M5 | $60.5M5 | |
| Shares outstanding | 989.0K shares3 | 22.6M shares4 | 25.8M shares5 | 26.1M shares5 | 26.1M shares9 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Cash from operations | -$27.2M3 | -$36.8M4 | -$49.8M5 | -$61.7M5 | ||
| Depreciation and amortization | $1.9M5 | $3.6M5 | ||||
| Stock-based compensation | $6.6M5 | $7.2M5 | ||||
| Capital spending | $977.0K3 | $1.1M4 | $9.5M5 | $19.9M5 | ||
| Free cash flow | -$28.2M | -$37.9M | -$59.4M | -$81.6M | ||
| Cash from investing | -$32.7M5 | -$33.0M5 | ||||
| Cash from financing | $53.6M5 | $19.7M5 |
Corporate structure
Oncorus, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Oncorus, Inc.
- CITADEL ADVISORS LLC Filed SC 13G/A on Oncorus, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- CHI Advisors LLC Filed SC 13G/A on Oncorus, Inc., latest Feb 13, 2023 (2 filings since Feb 11, 2022)
- Moshe Arkin Filed SC 13G/A on Oncorus, Inc., latest Feb 2, 2023 (2 filings since Dec 2, 2021)
- James E. Flynn Filed SC 13D/A on Oncorus, Inc., latest Jan 19, 2023 (4 filings since Dec 22, 2022)
- K2 HealthVentures Equity Trust LLC Filed SC 13G on Oncorus, Inc., latest Nov 1, 2022
- BlackRock Filed SC 13G on Oncorus, Inc., latest Jul 8, 2022 (2 filings since Feb 4, 2022)
- PERCEPTIVE ADVISORS LLC Filed SC 13G/A on Oncorus, Inc., latest Feb 15, 2022
- Oncorus, Inc. Andover, Massachusetts
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Oncorus, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Leasehold improvements | $14.9M5 Dec 31, 2022 | $13.2M4 Dec 31, 2021 | +12.9% |
| Property and equipment, before depreciation | $49.7M5 Dec 31, 2022 | $29.4M5 Dec 31, 2021 | +69.2% |
| Accumulated depreciation | $5.4M5 Dec 31, 2022 | $6.2M5 Dec 31, 2021 | −13.0% |
| Property and equipment, net | $44.4M5 Dec 31, 2022 | $23.2M5 Dec 31, 2021 | +90.9% |
| Operating-lease assets (leased space) | $32.6M5 Dec 31, 2022 | $45.2M5 Dec 31, 2021 | −28.0% |
Investments
Leadership
Who has led Oncorus, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2025
- Chief executive officerBrian J. Shea Jun 16, 2023 to Jun 16, 202310
- Chief executive officerTheodore Ashburn Oct 1, 2020 to Mar 2, 202211
- PresidentTheodore Ashburn Oct 1, 2020 to Mar 2, 202211
- Chief financial officerAlexander Nolte May 22, 2023 to May 22, 202312
- Chief financial officerRick Wanstall May 12, 2022 to May 25, 202213
- Chief financial officerJohn P. McCabe Oct 1, 2020 to Mar 2, 202214
- Chief operating officerStephen Harbin Dec 9, 2020 to Nov 2, 202215
Board members and other officers (14)
- CSO and SVP, ResearchChristophe Queva Oct 1, 2020 to Mar 2, 202216
- Board memberDouglas Fambrough Jun 24, 2022 to Jun 24, 202217
- Board memberEric Rubin Jun 17, 2021 to Jun 24, 202218
- Board memberBarbara Yanni Jul 29, 2021 to Jun 24, 202219
- Board memberBriggs Morrison Oct 1, 2020 to Oct 1, 202020
- Board memberCameron Wheeler Oct 1, 2020 to Oct 1, 202021
- Board memberJames E. Flynn Oct 1, 2020 to Feb 18, 202122
- Board memberLuke Evnin Oct 1, 2020 to Jun 24, 202223
- Board memberMary Kay Fenton Oct 1, 2020 to Jun 24, 202224
- Board memberMgmt Hif L.p. Deerfield Oct 1, 2020 to Feb 18, 202122
- Board memberMitchell H. Finer Oct 1, 2020 to Jun 24, 202225
- Board memberSpencer Nam Oct 1, 2020 to Jun 24, 202226
- Board memberTheodore Ashburn Oct 1, 2020 to Mar 2, 202211
- Board memberScott A. Canute Dec 16, 2020 to Jun 24, 202227
Timeline
- Aug 3, 20238-K Executive or director change; Shareholder vote; Other events28
- Jul 28, 20238-K Executive or director change; Bylaws or fiscal year changed; Shareholder vote29
- Jul 19, 20238-K Ended a material agreement; Executive or director change30
- Jun 26, 20238-K Regulation FD disclosure31
- Jun 16, 2023New chief executive Brian J. Shea becomes CEO10
- Jun 9, 20238-K Listing notice or transfer32
- Jun 7, 20238-K Executive or director change; Other events33
- Jun 1, 20238-K Exit or restructuring costs; Executive or director change; Other events34
- May 22, 20238-K Results of operations35
- May 18, 20238-K Ended a material agreement; Debt or obligation accelerated; Executive or director change36
- May 5, 20238-K Listing notice or transfer37
- May 1, 20238-K Executive or director change38
- Mar 24, 20238-K Results of operations39
- Oct 1, 2020New chief executive Theodore Ashburn becomes CEO11
Calendar
When it reported results
- May 22, 2023Reported quarterly or annual results35
- Mar 24, 2023Reported quarterly or annual results39
- Nov 2, 2022Reported quarterly or annual results40
- Aug 4, 2022Reported quarterly or annual results41
- May 4, 2022Reported quarterly or annual results42
- Mar 9, 2022Reported quarterly or annual results43
- Nov 3, 2021Reported quarterly or annual results44
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
104 filings to the SEC since October 2021: 4 annual reports, 5 quarterly reports, 31 major events, 30 insider forms, 14 large holders, 20 other. The latest 20:
- Aug 7, 2023DEFA14A EDGAR
- Aug 3, 202315-12G EDGAR
- Aug 3, 2023DEFA14A EDGAR
- Aug 3, 20238-K EDGAR
- Jul 28, 2023DEFA14A EDGAR
- Jul 28, 20238-K EDGAR
- Jul 19, 2023RW EDGAR
- Jul 19, 2023S-8 POS EDGAR
- Jul 19, 2023S-8 POS EDGAR
- Jul 19, 2023S-8 POS EDGAR
- Jul 19, 2023S-8 POS EDGAR
- Jul 19, 20238-K EDGAR
- Jun 26, 20238-K EDGAR
- Jun 23, 2023DEF 14A EDGAR
- Jun 16, 20233 FORM 3 SUBMISSION EDGAR
- Jun 12, 2023PRE 14A EDGAR
- Jun 9, 20238-K EDGAR
- Jun 7, 20238-K EDGAR
- Jun 1, 20238-K EDGAR
- May 22, 20233 FORM 3 SUBMISSION EDGAR
The 104 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
19 open-market trades by officers, directors and large owners since October 2021: 8 buys and 11 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 30, 2022 | Flynn James E | Sale | 138,872 | $0.27 | $37.5K | Form 4 |
| Dec 29, 2022 | Flynn James E | Sale | 141,753 | $0.26 | $36.9K | Form 4 |
| Dec 28, 2022 | Flynn James E | Sale | 55,610 | $0.25 | $13.9K | Form 4 |
| Dec 27, 2022 | Deerfield Mgmt HIF, L.P. | Sale | 65,090 | $0.27 | $17.6K | Form 4 |
| Dec 22, 2022 | Deerfield Mgmt HIF, L.P. | Sale | 8,294 | $0.28 | $2.3K | Form 4 |
| Dec 21, 2022 | Flynn James E | Sale | 13,800 | $0.30 | $4.1K | Form 4 |
| Dec 20, 2022 | Flynn James E | Sale | 14,740 | $0.31 | $4.6K | Form 4 |
| Dec 19, 2022 | Flynn James E | Sale | 99,718 | $0.29 | $28.9K | Form 4 |
| Dec 15, 2022 | Deerfield Healthcare Innovations Fund, L.P. | Sale | 3,089 | $0.39 | $1.2K | Form 4 |
| Dec 14, 2022 | Deerfield Healthcare Innovations Fund, L.P. | Sale | 8,600 | $0.38 | $3.3K | Form 4 |
| Dec 13, 2022 | Deerfield Healthcare Innovations Fund, L.P. | Sale | 2,097 | $0.41 | $860 | Form 4 |
| May 25, 2022 | Wanstall RickCFO and Treasurer | Buy | 3,777 | $1.20 | $4.5K | Form 4 |
| May 20, 2022 | Wanstall RickCFO and Treasurer | Buy | 1,610 | $1.20 | $1.9K | Form 4 |
| May 19, 2022 | Wanstall RickCFO and Treasurer | Buy | 5,000 | $1.29 | $6.5K | Form 4 |
| May 17, 2022 | Wanstall RickCFO and Treasurer | Buy | 1 | $1.20 | $1 | Form 4 |
| May 16, 2022 | Wanstall RickCFO and Treasurer | Buy | 20,620 | $1.18 | $24.3K | Form 4 |
| May 13, 2022 | Wanstall RickCFO and Treasurer | Buy | 3,898 | $1.15 | $4.5K | Form 4 |
| May 12, 2022 | Wanstall RickCFO and Treasurer | Buy | 14,094 | $1.08 | $15.2K | Form 4 |
| Nov 16, 2021 | Harbin StephenCOO and Chief of Staff | Buy | 30,000 | $5.79 | $173.7K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- CITADEL ADVISORS LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202345
- CHI Advisors LLCSC 13G/A, 2 filings Feb 11, 2022 to Feb 13, 202346
- Moshe ArkinSC 13G/A, 2 filings Dec 2, 2021 to Feb 2, 202347
- James E. FlynnSC 13D/A, 4 filings Dec 22, 2022 to Jan 19, 202348
- K2 HealthVentures Equity Trust LLCSC 13G, 1 filing Nov 1, 202249
- BlackRockSC 13G, 2 filings Feb 4, 2022 to Jul 8, 202250
- PERCEPTIVE ADVISORS LLCSC 13G/A, 1 filing Feb 15, 202251
SEC filer profile
How Oncorus, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGAROncorus, Inc.1
- CIK0001671818
- Employer ID (EIN)47-37797571
- Filer status<br>emerging growth company1
- Incorporated inDelaware1
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- Business address4 Corporate Drive, Andover, MA 018101
- Phone857-320-64001
- Shares outstanding26,094,847 as of May 20, 20238
- Public float$25.9M as of Jun 30, 20229
- On EDGAR sinceApr 14, 20161
- Filings222 in all: 4 (58), 8-K (45), 3 (24), 10-Q (8), CORRESP (8), SC 13G (7), SC 13G/A (7), UPLOAD (6)1
All 36 form types
D/A (4), DEFA14A (4), S-8 (4), S-8 POS (4), SC 13D/A (4), 10-K (3), DEF 14A (3), DRS/A (3), EFFECT (3), 10-K/A (2), 424B4 (2), D (2), DRS (2), DRSLTR (2), S-1 (2), SC 13D (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 4/A (1), 424B5 (1), 8-A12B (1), CERT (1), NT 10-Q (1), PRE 14A (1), RW (1), S-1/A (1), S-3 (1)
- Latest filingsAnnual report (10-K) Mar 24, 2023
Quarterly report (10-Q) May 22, 2023
Proxy statement (DEF 14A) Jun 23, 2023
Latest 8-K (8-K) Aug 3, 2023
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGAROncorus, Inc. filings on SEC EDGAR
- 2SEC EDGAROncorus, Inc. filings on SEC EDGAR
- 3SEC EDGAROncorus, Inc. 10-K for fiscal 2019
- 4SEC EDGAROncorus, Inc. 10-K for fiscal 2020
- 5SEC EDGAROncorus, Inc. 10-K for fiscal 2021
- 6SEC EDGAROncorus, Inc. 10-Q for fiscal 2022
- 7SEC EDGAROncorus, Inc. 10-Q for fiscal 2022
- 8SEC EDGAROncorus, Inc. 10-Q for fiscal 2023
- 9SEC EDGAROncorus, Inc. 10-K for fiscal 2023
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17SEC EDGARDouglas Fambrough, Board member
- 18SEC EDGAREric Rubin, Board member
- 19SEC EDGARBarbara Yanni, Board member
- 20SEC EDGARBriggs Morrison, Board member
- 21SEC EDGARCameron Wheeler, Board member
- 22SEC EDGARJames E. Flynn, Board member
- 23SEC EDGARLuke Evnin, Board member
- 24SEC EDGARMary Kay Fenton, Board member
- 25SEC EDGARMitchell H. Finer, Board member
- 26SEC EDGARSpencer Nam, Board member
- 27SEC EDGARScott A. Canute, Board member
- 28
- 29
- 30
- 31SEC EDGARRegulation FD disclosure
- 32SEC EDGARListing notice or transfer
- 33
- 34
- 35SEC EDGARResults of operations
- 36
- 37SEC EDGARListing notice or transfer
- 38SEC EDGARExecutive or director change
- 39SEC EDGARResults of operations
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50SEC EDGARBlackRock SC 13G on Oncorus, Inc.
- 51
- 52SEC EDGAROncorus, Inc. filing with the SEC